Master Regulator Gene Could Lead to Ovarian Cancer Treatments
Researchers at the University of Maryland School of Medicine have identified a “master regulator” gene, ZNFX1, that might serve as a biomarker for guiding treatment in therapy-resistant ovarian cancer. High levels of ZNFX1 correlate with better responses to certain therapies and increased overall survival, particularly when patients receive bevacizumab combined with chemotherapy. Also, two cancer drugs — DNA methyltransferase inhibitors and PARP inhibitors — can boost ZNFX1 expression, potentially enhancing tumor-suppressing inflammatory responses in cancer cells.